Status:
COMPLETED
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
35-75 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
Eligibility Criteria
Inclusion
- Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed \> 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and peripheral vascular disease (PVD).
- Participants that smoke \> 10 cigarettes / day.
Exclusion
- Participants with unstable cardiovascular disease
- Cardiovascular events in the past 2 months
- Moderate or severe chronic obstructive pulmonary disease (COPD)
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
714 Patients enrolled
Trial Details
Trial ID
NCT00282984
Start Date
February 1 2006
End Date
August 1 2008
Last Update
April 5 2017
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hartford, Connecticut, United States, 06102-5037
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
3
Pfizer Investigational Site
Madison, Wisconsin, United States, 53711
4
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina, 1181